Exome Asset Management LLC Makes New $264,000 Investment in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Exome Asset Management LLC bought a new position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 102,631 shares of the company’s stock, valued at approximately $264,000. Exome Asset Management LLC owned 0.27% of Leap Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in LPTX. Geode Capital Management LLC boosted its holdings in shares of Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares in the last quarter. HighTower Advisors LLC purchased a new stake in Leap Therapeutics in the third quarter worth about $65,000. Valence8 US LP purchased a new stake in Leap Therapeutics in the third quarter worth about $48,000. Simplify Asset Management Inc. increased its stake in shares of Leap Therapeutics by 67.4% during the third quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company’s stock valued at $2,716,000 after purchasing an additional 425,626 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its holdings in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock valued at $827,000 after purchasing an additional 37,067 shares during the last quarter. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a research report on Friday, November 15th.

Leap Therapeutics Stock Performance

NASDAQ:LPTX opened at $2.95 on Friday. The firm has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $2.59. The firm has a market cap of $113.04 million, a P/E ratio of -1.53 and a beta of 0.21. Leap Therapeutics, Inc. has a fifty-two week low of $1.68 and a fifty-two week high of $5.00.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.